MariusMessemaker
@MariusMessemak1
Passionate about improving cancer immunotherapy through the use of single-cell and bioinformatics approaches, PhD student @Schumacher_lab
Antidepressant efficacy is inflated by the cumulative impact of publication bias, outcome reporting bias, spin, and citation bias on the evidence base. 🧵1/12
Incredibly excited and grateful for the opportunity to present at Antwerp TCR in 3 weeks. There’s no place more relevant to showcase what we have been up to. If you want to have a sneak preview; check out the thread of @MariusMessemak1 & our pre-print biorxiv.org/content/10.110…
#ATCR25 acceptance notifications just went out! We had 76 abstracts of very high quality, but could only accept 8! for short talks (so 10%). Huge thanks to our review committee for making though decisions. Really excited where the #TCR field is going based on the abstracts I saw!
Very important work! We've been waiting for someone to do this. It has been clear for some time that a proportion of aggregated TCR-pMHC data might not be reliable. It will be interesting to reassess performance in light of this more robustly validated data.
It's not the models, it's the data! We show that a substantial proportion of a widely used TCR-pMHC database does not functionally validate, causing underestimation of performance of TCR-pMHC prediction models.
It's not the models, it's the data! We show that a substantial proportion of a widely used TCR-pMHC database does not functionally validate, causing underestimation of performance of TCR-pMHC prediction models.
A functionally validated TCR-pMHC database for TCR specificity model development biorxiv.org/content/10.110… #biorxiv_immuno
Ton Schumacher is closing #CancerHostTI24 discussing neoantigens and neoadjuvant therapy. With his research group he created technologies to dissect T cell responses in cancer and contributed to the development of adoptive T cell therapies and neoadjuvant cancer immunotherapy.